CURAPHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CURAPHARMA
Largest movements
- Cash -€37,822
down €37,822 (-38.4%), from €98,567 to €60,745
mainly Other debts (-€34,940) and Receivables within one year (-€15,725)
- Receivables within one year +€15,725
up €15,725 (+13.4%), from €116,981 to €132,705
of which Trade receivables: +€13,473
- Stocks and contracts -€7,669
down €7,669 (-4.9%), from €155,500 to €147,831
- Tangible fixed assets -€4,229
down €4,229 (-31.6%), from €13,378 to €9,149
of which Plant, machinery and equipment: -€3,684
- Other debts -€34,940
down €34,940 (-25.5%), from €136,894 to €101,954
- Profit (loss) carried forward +€7,040
up €7,040 (+9.6%), from €73,163 to €80,204
- Trade debts -€5,245
down €5,245 (-4.4%), from €118,153 to €112,909
- Gross operating margin -€5,888
down €5,888 (-25.3%), from €23,315 to €17,427
- Financial charges -€1,222
down €1,222 (-24.6%), from €4,960 to €3,739
- Depreciation -€1,147
down €1,147 (-21.3%), from €5,376 to €4,229
- Taxes -€817
down €817 (-25.6%), from €3,193 to €2,377
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €386,690 | €352,271 | -€34,419 | -8.9% |
| Fixed assets | 21/28 | €14,329 | €10,100 | -€4,229 | -29.5% |
| Tangible fixed assets | 22/27 | €13,378 | €9,149 | -€4,229 | -31.6% |
| Land and buildings | 22 | €5,488 | €5,251 | -€238 | -4.3% |
| Plant, machinery and equipment | 23 | €7,582 | €3,898 | -€3,684 | -48.6% |
| Other tangible fixed assets | 26 | €308 | - | -€308 | |
| Financial fixed assets | 28 | €951 | €951 | = | 0.0% |
| Current assets | 29/58 | €372,361 | €342,170 | -€30,190 | -8.1% |
| Stocks and contracts in progress | 3 | €155,500 | €147,831 | -€7,669 | -4.9% |
| Stocks | 30/36 | €155,500 | €147,831 | -€7,669 | -4.9% |
| Amounts receivable within one year | 40/41 | €116,981 | €132,705 | +€15,725 | +13.4% |
| Trade receivables | 40 | €101,839 | €115,312 | +€13,473 | +13.2% |
| Other amounts receivable | 41 | €15,141 | €17,393 | +€2,251 | +14.9% |
| Cash at bank and in hand | 54/58 | €98,567 | €60,745 | -€37,822 | -38.4% |
| Deferred charges and accrued income | 490/1 | €1,314 | €890 | -€424 | -32.3% |
| Total equity and liabilities | 10/49 | €386,690 | €352,271 | -€34,419 | -8.9% |
| Equity | 10/15 | €127,861 | €134,902 | +€7,040 | +5.5% |
| Contributions | 10/11 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €42,298 | €42,298 | = | 0.0% |
| Distributable reserves | 133 | €42,298 | €42,298 | = | 0.0% |
| Profit (loss) carried forward | 14 | €73,163 | €80,204 | +€7,040 | +9.6% |
| Amounts payable | 17/49 | €258,828 | €217,369 | -€41,459 | -16.0% |
| Amounts payable within one year | 42/48 | €255,499 | €214,862 | -€40,637 | -15.9% |
| Trade debts | 44 | €118,153 | €112,909 | -€5,245 | -4.4% |
| Suppliers | 440/4 | €118,153 | €112,909 | -€5,245 | -4.4% |
| Taxes, remuneration and social security | 45 | €452 | - | -€452 | |
| Taxes | 450/3 | €452 | - | -€452 | |
| Other amounts payable | 47/48 | €136,894 | €101,954 | -€34,940 | -25.5% |
| Accrued charges and deferred income | 492/3 | €3,329 | €2,507 | -€822 | -24.7% |
| Non-recurring operating income | 76A | - | €1,445 | +€1,445 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €5,376 | €4,229 | -€1,147 | -21.3% |
| Other operating charges | 640/8 | €399 | €400 | +€0 | +0.1% |
| Gross operating margin | 9900 | €23,315 | €17,427 | -€5,888 | -25.3% |
| Operating profit (loss) | 9901 | €17,540 | €12,798 | -€4,742 | -27.0% |
| Financial income | 75/76B | €401 | €357 | -€44 | -11.0% |
| Recurring financial income | 75 | €401 | €357 | -€44 | -11.0% |
| Financial charges | 65/66B | €4,960 | €3,739 | -€1,222 | -24.6% |
| Recurring financial charges | 65 | €4,960 | €3,739 | -€1,222 | -24.6% |
| Profit (loss) for the period before taxes | 9903 | €12,981 | €9,417 | -€3,564 | -27.5% |
| Income taxes | 67/77 | €3,193 | €2,377 | -€817 | -25.6% |
| Profit (loss) for the period | 9904 | €9,787 | €7,040 | -€2,747 | -28.1% |
| Profit (loss) for the period to be appropriated | 9905 | €9,787 | €7,040 | -€2,747 | -28.1% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.